Pancreatic Cancer Research

ResearcherFujian Medical UniversityNo recent work listed

Xiang Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1003-9892; OpenAlex author ID A5100368911. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2021: 1 paper · 2022: 5 papers · 2023: 4 papers

Papers 10

  1. [18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00259-023-06271-8↗
  2. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05715-1↗
  3. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05939-1↗
  4. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1. Co-author DOI 10.3892/ijo.2023.5493↗
  5. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Co-author DOI 10.1186/s12943-022-01501-3↗
  6. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway. Last author DOI 10.1186/s13062-022-00347-5↗
  7. N6-methyladenosine-mediated CELF2 regulates CD44 alternative splicing affecting tumorigenesis via ERAD pathway in pancreatic cancer. Co-author DOI 10.1186/s13578-022-00844-0↗
  8. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by competitively sponging miR-139-5p and activating the W… Co-author DOI 10.21203/rs.3.rs-1242747/v1↗
  9. METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification. First author DOI 10.3389/fonc.2022.962204↗
  10. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Co-author DOI 10.18632/aging.202922↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangeng Weng · 6 shared papers, 2022–2023 · strength 1.06
  2. Shihui Lai · 5 shared papers, 2022–2023 · strength 0.89
  3. Chengjie Lin · 5 shared papers, 2022–2023 · strength 0.88
  4. Yan Wang · 4 shared papers, 2022–2023 · strength 0.70
  5. Zhenyun Guo · 3 shared papers, 2022–2023 · strength 0.55
  6. Yue Huang · 3 shared papers, 2022–2023 · strength 0.55
  7. Liang Wang · 3 shared papers, 2022 · strength 0.51
  8. Chonghui Hu · 3 shared papers, 2021–2023 · strength 0.49
  9. Shangyou Zheng · 3 shared papers, 2021–2023 · strength 0.49
  10. Renpeng Xia · 2 shared papers, 2022–2023 · strength 0.33
  11. Rihua He · 2 shared papers, 2022–2023 · strength 0.33
  12. Rufu Chen · 2 shared papers, 2021–2022 · strength 0.30
  13. Jinbo Yue · 1 shared paper, 2023 · strength 0.18
  14. Ziyuan Zhu · 1 shared paper, 2023 · strength 0.18
  15. Rufu Chen · 1 shared paper, 2023 · strength 0.18
  16. Chengjie Lin · 1 shared paper, 2022 · strength 0.17
  17. Yun Zhong · 1 shared paper, 2022 · strength 0.16
  18. Hongcao Lin · 1 shared paper, 2021 · strength 0.16
  19. Quanbo Zhou · 1 shared paper, 2021 · strength 0.16
  20. Guolin Li · 1 shared paper, 2022 · strength 0.15
  21. Zhihua Li · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.